Boiled Peanut Immunotherapy for the Treatment of Peanut Allergy

Peanut Hypersensitivity Clinical Trial

— BOPI-2  

Official title:

Boiled Peanut Immunotherapy for the Treatment of Peanut Allergy: A Non-inferiority Study

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT03937726
• Other study ID #: 19SM5033
• Status: Active, not recruiting
• Phase: N/A
• Start date: April 29, 2019
• Est. completion date: May 2027

Study information

• Verified date: October 2023
• Source: Imperial College London
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Peanut allergy is the most common cause of severe allergic reactions to food. Onset is common in childhood, but in contrast to other food allergies such as cow's milk and egg, peanut allergy tends to persist into adulthood. It is associated with a significant impact on quality of life, both for the affected individual and their family.

There is no current cure for peanut allergy. Oral peanut immunotherapy (OIT) using defatted, roasted peanut flour has been demonstrated to offer potential in this regard, but is associated with significant and frequent reactions and can cause life-threatening allergic symptoms.

The investigators have previously demonstrated that the processing of peanuts through boiling results in a relatively hypoallergenic product due to the loss of key allergenic components from peanut into the water. This has been tested in a recently-completed Phase 2b/3 trial (The BOPI Study, Clinicaltrials.gov NCT02149719; HRA reference 15/LO/0287): 47 children/ young people with peanut allergy confirmed at double-blind, placebo-controlled food challenge (DBPCFC) were randomised (2:1) to receive either oral immunotherapy (updosing using boiled peanut for ~6 months, followed by maintenance with roasted peanut) or standard treatment (allergen avoidance). Participants underwent repeat DBPCFC at 12 months to assess response, following which peanut OIT was stopped and sustained unresponsiveness assessed after 4 weeks (4SU). 24/32 participants (100% per protocol) achieved the primary outcome of desensitisation to >1.44g peanut protein (approximately 6-8 peanuts, p<0.0001); of those 14 tolerated >4.4g peanut protein. 13/24 participants achieved 4SU. There was no significant change in threshold in the control group (p>0.05). Boiled peanut OIT had a favourable safety profile, with under 2% of doses associated with gastrointestinal symptoms.

The BOPI-2 study is a non-inferiority study to demonstrate that boiled peanut is at least as effective as peanut flour in treating children with peanut allergy. The study will compare the rate of adverse events and other safety outcomes between these two interventions, and assess the immunological mechanisms involved, a secondary aim being to develop clinically-useful predictors for identifying individuals likely to undergo successful desensitisation.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 83
• Est. completion date: May 2027
• Est. primary completion date: May 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 7 Years to 18 Years

Eligibility

Inclusion Criteria:

• Age 7-18 years (enrolment up to a participant's 19th birthday).

• Past history consistent with IgE-mediated peanut allergy

• Allergic to =1.44 g peanut protein (approx. 6 peanuts) at baseline double-blind placebo-controlled food challenge, prior to treatment allocation

• Tolerates at least 1/8 boiled peanut (boiled for 4 hours) at open food challenge at screening.

• Written informed consent of parent/legal guardian and patient assent.

Exclusion Criteria:

• Required previous admission to an intensive care unit for management of an allergic reaction to peanut.

• Clinically significant chronic illness (other than asthma, rhinitis or eczema).

• Undergoing subcutaneous or sublingual immunotherapy to respiratory allergens, and not yet established on maintenance dosing for at least 3 months.

• Undergoing oral immunotherapy for food allergy and within the first year of treatment.

• Subjects receiving anti-IgE therapy, oral immunosuppressants, beta-blocker or ACE inhibitor.

• Tolerance to =1.44 g peanut protein (approx. 6 peanuts) at initial DBPCFC during screening.

• Dose-limiting symptoms to 1/8 boiled peanut (boiled for 4 hours) at screening.

• Poorly controlled asthma within the previous 3 months (as defined by clinician judgement with reference to the ICON consensus ), or asthma requiring treatment with >5 days oral corticosteroids within the previous 3 months.

• Pregnancy

• Unwilling or unable to fulfil study requirements

Related Conditions & MeSH terms

• Hypersensitivity
• IgE Mediated Peanut Allergy
• Peanut Hypersensitivity

Intervention

Other:
• Boiled peanut
Desensitisation using boiled peanut for induction and initial updosing
• Defatted roasted peanut flour
Desensitisation using defatted peanut flour for induction and initial updosing

Locations

Country	Name	City	State
United Kingdom	Imperial College Healthcare NHS Trust (St. Mary's Hospital)	London

Sponsors (2)

Lead Sponsor	Collaborator
Imperial College London	University College Cork

Country where clinical trial is conducted

United Kingdom, 

References & Publications (1)

Muraro A, Dubois AE, DunnGalvin A, Hourihane JO, de Jong NW, Meyer R, Panesar SS, Roberts G, Salvilla S, Sheikh A, Worth A, Flokstra-de Blok BM; European Academy of Allergy and Clinical Immunology. EAACI Food Allergy and Anaphylaxis Guidelines. Food allergy health-related quality of life measures. Allergy. 2014 Jul;69(7):845-53. doi: 10.1111/all.12405. Epub 2014 May 2. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Sustained unresponsiveness after 4 weeks cessation of maintenance OIT	Rate of sustained unresponsiveness after 4 weeks cessation of maintenance OIT at 1 year.	After 1 year of OIT
Other	Sustained unresponsiveness after 12+ weeks cessation of maintenance OIT	Rate of sustained unresponsiveness after 12+ weeks cessation of maintenance OIT at 1 year, in those participants who demonstrate sustained unresponsiveness at 4 weeks off maintenance OIT.	After 1 year of OIT
Primary	Desensitisation to >1.4g (roasted) peanut protein at food challenge	The proportion of participants who tolerate 1.44g (or more) roasted peanut protein (equivalent to = 6 roasted peanuts) after 12 months of OIT, as assessed by DBPCFC, in each treatment group.	12 months
Secondary	Adverse events	The proportion of participants experiencing adverse events classified as mild non-transient symptoms or more severe during updosing and maintenance in each treatment group.	12 months
Secondary	Other safety outcomes	Rates of adverse events by type / organ involved in each treatment group	12 months
Secondary	Change in Health-related quality of life (HRQL) from baseline - assessed using FAQLQ	Change in HRQL measures at 6, 12 and 13 months from baseline, as assessed in study participants and their parent/carer using the following validated questionnaire: - Food Allergy Quality of Life Questionnaire (FAQLQ) (reference Muraro et al, 2014)	6,12 and 13+ months
Secondary	Change in Health-related quality of life (HRQL) from baseline - assessed using FAIM	Change in HRQL measures at 6, 12 and 13 months from baseline, as assessed in study participants and their parent/carer using the following validated questionnaire: - Food Allergy Independent Measure (FAIM) (see Muraro et al, 2014)	6,12 and 13+ months
Secondary	Change in Health-related quality of life (HRQL) from baseline - assessed using standardized instrument (EQ-5D)	Change in HRQL measures at 6, 12 and 13 months from baseline, as assessed using the following validated questionnaire: - EQ-5D - a standardized instrument for use as a measure of health outcome. (Further details at https://euroqol.org/)	6,12 and 13+ months
Secondary	Change in Health-related quality of life (HRQL) from baseline - assessed using standardized instrument (CHU-9D)	Change in HRQL measures at 6, 12 and 13 months from baseline, as assessed using the following validated questionnaire: - CHU-9D (The Child Health Utility 9D) - also a standardized instrument for use as a measure of health outcome. (Further details at https://www.sheffield.ac.uk/scharr/sections/heds/mvh/paediatric)	6,12 and 13+ months
Secondary	Change in self-efficacy after each phase of immunotherapy	Change in self-efficacy at 6, 12 and 13 months from baseline, as assessed in study participants and their parent/carer using validated questionnaire.	6,12 and 13+ months
Secondary	Immunological outcome: skin prick test	Change in skin prick test wheal (mm) and end-point titration skin prick test between baseline and post immunotherapy	12 months
Secondary	Immunological outcome: Allergen-specific IgE	Change in allergen-specific IgE (kUa/l) between baseline and post immunotherapy	12 months

External Links

•   Related Info